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Abstract
Background: The efficacy of B cell-depleting therapies for rheumatoid arthritis underscores antibody-independent
functions of effector B cells such as cognate T–B interactions and production of pro-inflammatory cytokines.
Receptor activator of nuclear factor κB ligand (RANKL) is a key cytokine involved in bone destruction and is highly
expressed in synovial fluid B cells in patients with rheumatoid arthritis. In this study we sought to clarify the
generation mechanism of RANKL+ effector B cells and their impacts on osteoclast differentiation.
Methods: Peripheral blood and synovial fluid B cells from healthy controls and patients with rheumatoid arthritis
were isolated using cell sorter. mRNA expression of RANKL, osteoprotegerin, tumor necrosis factor (TNF)-α, and
Blimp-1 was analyzed by quantitative real-time polymerase chain reaction. Levels of RANKL, CD80, CD86, and CXCR3
were analyzed using flow cytometry. Functional analysis of osteoclastogenesis was carried out in the co-culture
system using macrophage RAW264 reporter cells.
Results: RANKL expression was accentuated in CD80+CD86+ B cells, a highly activated B-cell subset more abundantly
observed in patients with rheumatoid arthritis. Upon activation via B-cell receptor and CD40, switched-memory B cells
predominantly expressed RANKL, which was further augmented by interferon-γ (IFN-γ) but suppressed by interleukin-21.
Strikingly, IFN-γ also enhanced TNF-α expression, while it strongly suppressed osteoprotegerin expression in B cells. IFN-γ
increased the generation of CXCR3+RANKL+ effector B cells, mimicking the synovial B cell phenotype in patients with
rheumatoid arthritis. Finally, RANKL+ effector B cells in concert with TNF-α facilitated osteoclast differentiation in vitro.
Conclusions: Our current findings have shed light on the generation mechanism of pathogenic RANKL+ effector B cells
that would be an ideal therapeutic target for rheumatoid arthritis in the future.
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Background
Rheumatoid arthritis (RA) is a prototypical autoimmune
disease characterized by joint inflammation and bone
destruction. The synovium of RA exhibits abundant ac-
cumulation of immune and inflammatory cells such as
dendritic cells, T cells, B cells, macrophages and neutro-
phils [1]. The emergence of autoantibodies such as anti-
citrullinated protein antibodies (ACPA) and rheumatoid
factors (RF) in the preclinical stage of RA underscores
an autoimmune-driven process in this disease [2].
Among current biological therapies targeting immune
cells in RA, the advent of B cell-depleting agents, such
as rituximab (RTX), has prompted reappraisal of the role
of B cells in the pathogenesis of this disease [3–5]. Most
intriguingly, RTX significantly inhibits synovial inflam-
mation and bone destruction without reducing the titers
of autoantibodies. Pathogenic B cells in RA are thus
most likely to function as potent effectors mainly in an
antibody-independent manner, presumably via cognate
* Correspondence: hniiro@med.kyushu-u.ac.jp
2Clinical Education Center, Kyushu University Hospital, 3-1-1 Maidashi
Higashi-ku, Fukuoka 812-8582, Japan
Full list of author information is available at the end of the article
© 2016 Ota et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ota et al. Arthritis Research & Therapy  (2016) 18:67 
DOI 10.1186/s13075-016-0957-6
T–B interactions and release of pro-inflammatory cyto-
kines [6–9].
Receptor activator of nuclear factor κB ligand
(RANKL) is a pro-inflammatory cytokine of the tumor
necrosis factor (TNF) family and is a key positive regula-
tor of osteoclast development and activation that is per-
tinent to bone destruction. Previous studies showed that
RANKL is highly expressed in synovial fibroblasts and
activated T cells in RA [10–12]. A recent study, however,
suggests that synovial B cells are another important
source of RANKL in RA [13]. In addition, Fc-receptor-
like 4 (FcRL4)+ B cells, a unique B-cell subset observed
in RA synovium but not in the peripheral blood (PB),
are proposed as potent effectors expressing RANKL at
high levels, although the impact of RANKL+ B cells on
osteoclastogenesis has yet to be clarified [14].
The following issues remain to be addressed. First, it
remains largely elusive how RANKL+ effector B cells are
generated in RA. Given that T cell-derived cytokines
play a crucial role in T–B collaboration in RA, whether
these cytokines affect the generation of RANKL+ effector
B cells is of potential interest. In addition, since B cells
are also a potential source of negative regulators for os-
teoclastogenesis, such as osteoprotegerin (OPG), a decoy
receptor for RANKL, the impact of RANKL+ effector B
cells on osteoclastogenesis needs to be carefully evalu-
ated [15–18].
In this study, based on the key finding that RANKL
was expressed at high levels in CD80+CD86+ B cells
from patients with RA, we demonstrate that, upon acti-
vation via B-cell receptor (BCR) and CD40, human
switched-memory B cells predominantly expressed
RANKL, which was further augmented by interferon
(IFN)-γ but suppressed by interleukin (IL)-21. Notably,
IFN-γ also enhanced TNF-α expression, while it strongly
suppressed OPG expression in B cells. IFN-γ increased
expression of CXC motif chemokine receptor 3 (CXCR3)
in RANKL+ B cells, mimicking the synovial B cell
phenotype in RA. Finally, RANKL+ effector B cells in
concert with TNF-α facilitated osteoclast differentiation
in vitro. Together, these findings have thrown light on
the generation mechanism of RANKL+ effector memory




Patients with RA met with the 1987 American College
of Rheumatology classification criteria. PB was obtained
from 24 patients with RA (PBRA; 3 males and 21 fe-
males, 21 to 75 years old, average age 60.0 years). Syn-
ovial fluid (SF) was obtained from 8 patients with RA
(SFRA; 1 male and 7 females, 22 to 85 years old, average
age 60.6 years). PB from healthy controls (PBHC)
matched to the RA patients’ gender and age served as
controls. Patient details are provided in Additional file 1
(Table S1). Informed consent was obtained from all sub-
jects in accordance with the Declaration of Helsinki.
The Institutional Review Board of Kyushu University
Hospital approved all research on human subjects.
Reagents
An affiniPure F (ab’) Fragment Goat Anti-Human IgA/
IgG/IgM (H + L) (BCR, 10 μg/ml) was purchased from
Jackson ImmunoResearch (West Grove, PA, USA). Anti-
human CD40 monoclonal antibody (CD40, 2 μg/ml), re-
combinant human cytokines (TNF-α (100 ng/ml), IFN-γ
(20 ng/ml), IL-4 (20 ng/ml), IL-17 (100 ng/ml), IL-2
(100 ng/ml), IL-6 (100 ng/ml)), recombinant human IL-6
Receptor (100 ng/ml) and OPG (100 ng/ml)) were from
R&D Systems (Minneapolis, MN, USA). Recombinant
human CXC motif chemokine ligand 10 (CXCL10,
100 ng/ml) was from PeproTech Inc (Rocky Hill, NJ,
USA). Recombinant human IL-21(20 ng/ml) was from
Miltenyi Biotec (Auburn, CA, USA). CpG ODN 2006, type
C (Toll-like receptor 9 (TLR9), 0.1 μM) was from Gene
Design Inc (Osaka, Japan). A fully human monoclonal
antibody against RANKL (αRANKL, 100 ng/ml) was from
Amgen Inc (Thousand Oaks, CA, USA).
Isolation and cell sorting of B cell subsets
Mononuclear cells were isolated from PB and SF using a
density centrifugation with LSM (MP Biomedicals, LLC,
Santa Ana, CA, USA). B cells were isolated by positive
selection with Dynabeads M450 CD19 and DETACHa-
BEAD CD19 (Invitrogen, Carlsbad, CA, USA) as previously
described [19]. As we previously showed, only negligible
levels of artificial activation of B cells occurred immediately
after positive selection [20]. To avoid unwanted further
stimulation, cells were normally rested on ice prior to any
stimulation. Isolated B cells exhibited greater than 99.5 %
viability and more than 95 % purity, confirmed by flow cy-
tometry. Cells were stained with mouse or rabbit monoclo-
nal antibody (mAb) against human CD19, IgD, CD27,
CD80, CD86, CD183 (CXCR3), CD254 (RANKL) and
CD307d (FcRL4) (all from BioLegend, San Diego, CA,
USA). Naïve (IgD+CD27–), IgD+-memory (IgD+CD27+),
double-negative (IgD–CD27–) and switched-memory (IgD–
CD27+) B cell subsets were purified by flow cytometry.
Quantitative real-time polymerase chain reaction
Total RNA was extracted from primary B cells using Iso-
gen II reagent (Nippon Gene, Tokyo, Japan). First-strand
complementary DNA (cDNA) was synthesized using a
SuperScript III First-Strand Synthesis SuperMix (Invitro-
gen). Quantitative real-time polymerase chain reaction
(PCR) was performed in the ABI Prism 7500 Sequence
Detector (Applied Biosystems, Foster City, CA, USA).
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The reactions were performed in triplicate wells in 96-
well plates. TaqMan target mixes for TNFSF11
(Hs00243533_m1), TNF (Hs00174128_m1), TNFRSF11B
(Hs00900358_m1), PRDM1 (Hs00153357_m1) and
CXCR3 (Hs00171041_m1) were all purchased from Ap-
plied Biosystems. 18S ribosomal RNA was separately
amplified in the same plate as an internal control for
variation in the amount of cDNA in PCR. The collected
data were analyzed using Sequence Detector software
(Applied Biosystems). Data were expressed as the fold-
change in gene expression relative to the expression in
control cells.
Plasmid construction
The pE2-ctsk-Venus plasmid expressing Venus protein
under the control of cathepsin K (ctsk) promoter was
constructed. To prepare this plasmid, the CMV pro-
moter of pE2-Crimson-N1 (Clontech laboratories Inc,
CA, USA) was first replaced by the mouse Ctsk pro-
moter fragment (–1676 to –48) [21]. The fragment in-
cluding Crimson coding region of the resulting plasmid
was then replaced by the fragment including Venus cod-
ing region derived from pCS2-Venus vector kindly pro-
vided by Dr. A. Miyawaki (Brain Science Institute,
RIKEN, Japan).
Generation of RAW264 Venus reporter cells
The pE2-ctsk-Venus plasmid was linearized by ApaLI di-
gestion and transfected into RAW-D cells (sub-clone of
RAW264 [22]) by electroporation at 300 V and 950 μF
using a Gene Pulser Xcell (BioRad). Twenty-four hours
after transfection, cells were then selected by G418 (500
μg/ml) for 3 weeks to establish RAW-Ctsk-Venus cell
lines that can express Venus protein by addition of
RANKL (30 ng/ml). Among several clones, RAW-ctsk-
Venus1 (RAW-Venus1) clone with highest induction of
Venus protein was selected.
Analysis of osteoclast differentiation (osteoclastogenesis)
We first confirmed that differentiation of RAW-Venus1
cells into Venus-positive pre-osteoclasts and osteoclasts
were induced by RANKL in a dose-dependent manner
(Additional file 2: Figure S1). TNF-α exerted synergistic
effects on RANKL-induced osteoclast differentiation. In
addition, both anti-RANKL Ab and OPG strongly re-
duced the number of Venus-positive cells, indicating
the inhibition of osteoclast differentiation. RAW-
Venus1 cells were cultured at 2.25 × 104 cells/ml for 1
day in a 96-well plate and served as osteoclast precur-
sors. These cells were co-cultured with B cells at 2.25 ×
104 cells/well for 2 days and Venus-positive cells were
counted by Electrophysiological Microscopes (Keyence,
Osaka, Japan).
Statistical analysis
Numerical data in the in vitro experiments were pre-
sented as mean of the different experiments and stand-
ard error of the mean (SEM). The significance of the
differences was determined by Student's t-test for com-
paring differences between two groups, and one-way
analysis of variance for comparing differences between
multiple groups. In some experiments, Dunnett’s test
was applied. Numerical data in patient-sample analyses
were presented as mean, and the significance of differ-
ences (SD) was determined by Student’s t-test or non-
parametric Mann-Whitney U-test according to distribu-
tions. For all tests, P values less than 0.05 were considered
significant. Statistical analysis was performed with Graph-
Pad Prism 6 (GraphPad Software, La Jolla, CA, USA).
Results
Activation via BCR and CD40 induces RANKL expression
in CD80+CD86+ B cells
Although a previous study showed that RANKL+ B cells
are barely detected in human PB [13], we hypothesized
that a specific B-cell subpopulation might express high
levels of RANKL. CD80 and CD86 are surface markers
representing the status of highly activated B cells that
make cognate interaction with activated T cells. We first
tested the abundance of B-cell subsets defined by CD80
and CD86 staining in healthy controls (HC) and patients
with RA. The proportion of CD80+CD86+ B cells was sig-
nificantly higher in patients with RA than in HC (Fig. 1a).
In addition, such highly activated (CD80+CD86+) B cells
significantly expressed RANKL at higher levels than non-
activated (CD80–CD86–) B cells (Fig. 1b) in patients with
RA, suggesting that robust B-cell activation is required for
RANKL expression.
We thus sought to determine what conditions could in-
duce RANKL expression in B cells from HC. Robust activa-
tion of B cells via BCR, CD40 or TLR9 is involved in the
pathogenesis of autoimmune diseases. Compared with
TLR9, stimulation of BCR and, to a lesser extent, CD40 sig-
nificantly induced RANKL expression in B cells (Fig. 1c).
Co-stimulation of BCR and CD40 further enhanced
RANKL expression (Fig. 1d) and generated CD80+CD86+ B
cells expressing RANKL at high levels (Fig. 1e). These sug-
gest that robust activation of B cells via BCR and CD40
induces RANKL expression in CD80+CD86+ B cells.
BCR/CD40-induced RANKL expression in switched-memory
B cells is augmented by IFN-γ but suppressed by IL-21
To further determine the differences of RANKL expres-
sion in B-cell subsets, we sorted naïve B cells, IgD
+-memory B cells and switched-memory B cells from
HC. Without stimulation, RANKL was only weakly
expressed in all subsets; however, BCR/CD40 stimulation
induced expression of RANKL mRNA and protein at
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high levels predominantly in switched-memory B cells
(Fig. 2a).
Co-stimulation of BCR and CD40 in B cells mimics T
cell-dependent responses in vivo. Given that activated T
cells produce various cytokines, we next questioned
whether such cytokines could modulate BCR/CD40-in-
duced RANKL expression in switched-memory B cells.
Among cytokines tested, IFN-γ remarkably augmented
RANKL expression, while IL-21 significantly suppressed
it at both mRNA and protein levels (Fig. 2b, c). Of note,
BCR/CD40 stimulation of switched-memory B cells aug-
mented CD80 expression, which was however not af-
fected by either IFN-γ or IL-21 (Fig. 2b, right panel).
These results suggest that RANKL expression is
regulated by a mechanism distinct from CD80 expres-
sion in B cells with IFN-γ and IL-21.
B cells can also produce important regulators other than
RANKL for osteoclastogenesis. The pro-inflammatory
cytokine TNF-α concerts with RANKL to induce osteo-
clastogenesis, while OPG is decoy receptor for RANKL
and functions as a negative regulator of osteoclastogenesis.
Notably, IFN-γ stimulation increased TNF-α expression,
while it strongly suppressed OPG expression in switched-
memory B cells (Fig. 2c), thus tipping the balance more to-
wards osteoclastogenesis. IL-21 stimulation suppressed
both RANKL and OPG expression, while it upregulated
expression of Blimp-1, suggesting that IL-21 plays a crit-
ical role in plasma cell differentiation compared to
Fig. 1 Activation via B-cell receptor (BCR) and CD40 induces receptor activator of nuclear factor kappa-B ligand (RANKL) expression in CD80+CD86+ B
cells. a Freshly isolated PB B cells were stained with CD80 and CD86, and the proportion of each subset from 16 healthy controls (HC) and 24 patients
with rheumatoid arthritis (RA) was analyzed by flow cytometry. b RANKL expression was analyzed in each subset of 24 patients with RA. Representative
data are shown in (a) and (b). Horizontal lines show the mean (*P < 0.05, **P < 0.005). c Purified B cells from HC were stimulated for 24, 72 and 96 hours
via BCR, CD40 or Toll-like receptor 9 (TLR9). d Purified B cells from HC were stimulated for 24 hours via BCR and/or CD40. RANKL mRNA expression was
analyzed by quantitative PCR in (c) and (d). The values are the mean ± SEM of three independent experiments (n = 5, *P < 0.05, **P < 0.005).
e Purified B cells from HC were incubated for 48 hours with or without BCR/CD40 stimulation, and CD80, CD86 and RANKL expression were
analyzed by flow cytometry. The results shown are representative of three independent experiments. The values are the mean ± SEM (n = 4,
*P < 0.05). No stim no stimulation, NS not significant
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osteoclastogenesis [23]. Together, these results suggest
that T cell-derived IFN-γ strongly augments the gener-
ation of RANKL+ effector memory B cells.
IFN-γ increases CXCR3+RANKL+ effector memory B cells
The chemokine CXCL10, a ligand for CXCR3, is in-
creased in SFRA and attracts leukocytes to the inflam-
matory lesion [24–27]. Although BCR/CD40 stimulation
alone was without effect on CXCR3 expression, IFN-γ
significantly induced CXCR3 expression that was further
augmented by BCR/CD40 stimulation in switched-
memory B cells (Fig. 2d). Notably, CXCR3+ switched-
memory B cells mainly expressed RANKL that was
further pronounced by IFN-γ (Fig. 2d, right panel).
A previous report showed that CXCL10 stimulation
induces RANKL expression in CD4+ T cells in RA [28].
We thus tested the effect of CXCL10 on RANKL expres-
sion in switched-memory B cells. CXCL10 stimulation
Fig. 2 B-cell receptor (BCR)/CD40-induced receptor activator of nuclear factor kappa-B ligand (RANKL) expression in switched-memory B cells is
augmented by interferon gamma (IFN-γ) but is suppressed by interleukin-21 (IL-21). a Naïve (IgD+CD27–), IgD+-memory (IgD+-m, IgD+CD27+) and
switched-memory (Sw-m, IgD–CD27+) B cell subsets from HC were purified by flow cytometry and stimulated with or without BCR/CD40. RANKL
expression at mRNA and protein levels was detected by quantitative PCR and flow cytometry, respectively. The values are the mean ± SEM of
three independent experiments (n = 5, **P < 0.005, with reference to BCR/CD40-stimulated sw-m B cells). b Purified switched-memory B cells from
HC were incubated with IFN-γ, tumor necrosis factor alpha (TNF-α), IL-2, IL-4, IL-6 + IL-6 receptor, IL-17, or IL-21 in addition to BCR/CD40 simulation.
RANKL mRNA expression was analyzed by quantitative PCR (n = 4, *P < 0.05, with reference to BCR/CD40-stimulated sw-m B cells). Expression of RANKL
and CD80 was detected by flow cytometry (n = 4). c Purified switched-memory B cells from HC were stimulated via BCR/CD40, IFN-γ or IL-21, and
mRNA expression of indicated molecules was analyzed by quantitative PCR. The values are the mean ± SEM of three independent experiments (n = 4,
*P < 0.05, **P < 0.005, with reference to BCR/CD40-stimulated sw-m B cells). d Purified switched-memory B cells from HC were cultured with BCR/CD40
stimulation and/or IFN-γ, and CXCR3 mRNA expression was analyzed (n = 3, *P < 0.05, with reference to IFN-γ-stimulated sw-m B cells). Expression of
RANKL and CXCR3 was detected by flow cytometry (n = 7). e Purified switched-memory B cells from HC were stimulated with the indicated dose of
BCR/CD40 in the presence or absence of CXCL10 (100 ng/ml) and RANKL mRNA expression was analyzed. BCR/CD40 stimulation was carried
out at suboptimal or optimal dose (n = 3, *P < 0.05). a–e mRNA expression of each molecule was detected by quantitative PCR after 24 hours
culture. Expression of RANKL, CD80 and CXCR3 was detected after 48 hours culture. OPG osteoprotegerin, N.D. not determined, No stim no
stimulation, NS not significant
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increased RANKL expression with or without subopti-
mal BCR/CD40 stimulation (Fig. 2e). These results sug-
gest that IFN-γ increases the generation of CXCR3
+RANKL+ effector memory B cells, which are in turn re-
cruited to the inflammatory lesions such as the syno-
vium of RA patients. Thus, CXCL10 released at the
inflammatory sites not only attracts CXCR3+ switched-
memory B cells but also enhances their potential to pro-
duce RANKL.
CXCR3+RANKL+ B cells accumulate in SF of patients with
RA
We next questioned whether SF B cells in patients with
RA exhibit similar phenotype to CXCR3+RANKL+ ef-
fector memory B cells generated in vitro. The proportion
of CD80+CD86+ B cells was significantly higher in SF
(Fig. 3a) than in PB (Fig. 1a). Consistent with Fig. 1b,
highly activated (CD80+CD86+) B cells expressed
RANKL at high levels (Fig. 3a, far right panel). In
addition, double-negative (IgD–CD27–, a subset also in-
cluding abundant effector memory cells), and switched-
memory (IgD+CD27+) B cells were predominantly
enriched in SFRA (Fig. 3b, left panel), and RANKL ex-
pression in both subsets was significantly higher than
that in naïve B cells (Fig. 3b, far right panel). Further-
more, the proportion of CXCR3+RANKL+ B cells was
significantly higher in SFRA than in PBHC and PBRA
(Fig. 3c, middle panel). Consistent with Fig. 2d, synovial
CXCR3+ B cells expressed RANKL at higher levels than
CXCR3– B cells (Fig. 3c, right panel).
Together, these results suggest that the phenotype of
RANKL+ B cells in SF of patients with RA is quite akin
to that of in vitro-generated CXCR3+ effector memory B
cells, as shown above.
Fig. 3 CXCR3+RANKL+ B cells accumulate in synovial fluid (SF) of patients with rheumatoid arthritis (SFRA). a CD80 and CD86 expression was
analyzed in SF B cells from RA patients (n = 8). Receptor activator of nuclear factor kappa-B ligand (RANKL) expression in CD80–CD86– and
CD80+CD86+ SF B cells was analyzed by flow cytometry. b The proportion of naïve (IgD+CD27–), IgD+-memory (IgD+-m, IgD+CD27+), double-negative (DN)
and switched-memory (Sw-m, IgD–CD27+) B cells in SF, and RANKL expression of each subset was analyzed (n = 8). c The proportion of CXCR3+RANKL+ B
cells was analyzed in peripheral blood of healthy controls (PBHC, n = 13), peripheral blood of patients with RA (PBRA, n = 18) and SFRA (n = 8). CXCR3+ and
CXCR3– SF B cells from patients with RA were analyzed for mean fluorescence intensity (MFI) of RANKL expression by flow cytometry (n = 8, *P < 0.05). a–c
Box plots represent the median values, quartiles and extremes (*P < 0.05, **P< 0.005). Representative data are shown. NS not significant
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RANKL+ effector memory B cells in concert with TNF-α
facilitate osteoclastogenesis
Since switched-memory B cells abundantly produce both
positive (RANKL and TNF-α) and negative (OPG) regu-
lators of osteoclastogenesis (Fig. 2c), we directly tested
whether switched-memory B cells could induce osteo-
clast differentiation, using a clone of macrophage
RAW264 reporter cells (RAW-Venus1). This in vitro
system allowed us to monitor the initiation of osteoclast
differentiation by the detection of Venus positive cells.
Without stimulation, switched-memory B cells mar-
ginally induced Venus positive cells; however, upon
BCR/CD40 stimulation they remarkably induced Venus
expression, which was further enhanced by the addition
of IFN-γ (Fig. 4a, d). In this system, TNF-α alone also in-
duces Venus positive cells and synergistically enhances a
RANKL-dependent osteoclast differentiation. In the
presence of an excess amount of TNF-α, BCR/CD40-
stimulated switched-memory B cells induced more
Venus positive cells, a process suppressed by addition of
anti-RANKL mAb, validating the involvement of
RANKL in this process (Fig. 4b, d). Strikingly, co-
stimulation of activated B cells with IFN-γ and TNF-α
further increased Venus positive cells, and co-
localization of B cells and Venus cells was observed
(Fig. 4c, d). Together, these results suggest that, despite
their potential to produce OPG, switch-memory B cells
induce RANKL+ effector cells upon stimulation of BCR/
Fig. 4 RANKL+ effector memory B cells in concert with tumor necrosis factor alpha (TNF-α) facilitate osteoclastogenesis. a–c RAW-Venus1 cells
were co-cultured with switched-memory B cells at 2.25 × 104 cells/well for 2 days with or without BCR/CD40 stimulation, interferon gamma (IFN-γ,
20 ng/ml), TNF-α (100 ng/ml) or monoclonal antibody against receptor activator of nuclear factor kappa-B ligand (αRANKL, 100 ng/ml). Venus positive cells
were detected using the fluorescein isothiocyanate (FITC) channel. A field equaled an area of 0.39 mm2 (magnification × 20). c Venus positive
cells co-localized with switched-memory CD19+ B cells from HC. d Venus positive cells were counted in three randomly selected fields of
three to five independent experiments. Box plots represent the median values, quartiles and extremes (n = 9, *P < 0.05, **P < 0.005). BCR B-cell
receptor, DAPI 4’6-diamidino-2-phenylindole, No stim No stimulation, NS not significant
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CD40 and IFN-γ, and in concert with TNF-α facilitate
osteoclastogenesis.
Discussion
In this study we demonstrate that RANKL+ B cells were
enriched in the CD80+CD86+ subpopulation more fre-
quently in patients with RA. Activation via BCR and
CD40 induced switched-memory B cells to express
RANKL, which was further augmented by IFN-γ but
suppressed by IL-21. IFN-γ also enhanced TNF-α ex-
pression, while it strongly suppressed OPG expression in
B cells. IFN-γ increased CXCR3+RANKL+ B cells, mim-
icking the synovial B-cell phenotype in patients with RA.
RANKL+ effector memory B cells in concert with TNF-α
facilitated osteoclast differentiation in vitro. These find-
ings suggest that CXCR3+ RANKL+ switched-memory B
cells are potent pathogenic effectors in RA.
CD4+ T-cell subsets are defined on different patterns
of cytokine production that in turn affect B-cell func-
tions. Among T cell-derived cytokines tested, the Th1
cytokine IFN-γ most efficiently upregulated RANKL ex-
pression in BCR/CD40-stimulated switched-memory B
cells (Fig. 2). Most strikingly, IFN-γ simultaneously
inhibited OPG expression, thereby tipping the balance
more towards osteoclastogenesis. Indeed, a recent report
showed that citrulline-reactive memory Th1 but not
Th17 cells are more abundant in the PB of patients with
RA [29]. This suggests that RANKL+ switched-memory
B cells require cognate interaction with Th1 cells to
make them fully pathogenic effector B cells in RA. How
then are pathogenic Th1 and B cells recruited to and
maintained in the inflammatory site such as RA syno-
vium? The chemokine CXCL10, a ligand for CXCR3, is
abundantly secreted in RA synovium [24–27]. CXCR3 is
a phenotypic marker of Th1 cells and we previously
showed that Th1 but not Th17 cells predominate in the
joints of RA patients [30]. Likewise, RANKL+ B cells in
SFRA predominantly expressed CXCR3 (Fig. 3). In
addition, we found that CXCL10 stimulation via CXCR3
enhanced RANKL expression in B cells, thus suggesting
a vicious cycle for aggravation of bone destruction in
RA. It should be noted that anti-CXCL10 therapy shows
efficacy in patients with RA [31].
In addition to B cells, synovial fibroblasts and activated
T cells are the source of RANKL in RA synovium [10–12].
In mice, RANKL produced by synovial fibroblasts, but not
T cells, plays a pivotal role in bone erosions in inflamma-
tory arthritis [32]. The role of B cell-derived RANKL in
the pathogenesis of these rodent models of RA remains to
be clarified. However, in rodent models of periodontitis
(PD), gingival B cells abundantly express RANKL and B
cell depletion significantly protects alveolar bone loss
[33, 34]. Given that RA and PD share the similar fea-
tures of inflammation and bone destruction, and the
latter is indeed closely related to the pathogenesis of
the former [35], it is of potential interest to elucidate
the pathogenic role of human RANKL+ B cells in RA.
The role of specific cell types in osteoclastogenesis is
often simply extrapolated from their potential to express
RANKL. However, many cell types, including B cells,
simultaneously produce negative regulators of osteoclas-
togenesis such as OPG [16, 17]. Thus, the impact of B
cells on osteoclastogenesis needs to be carefully
evaluated.
During the preparation of this manuscript, Meednu et al
very recently showed that combinatorial stimulation with
anti-CD40 and phorbol 12-myristate 13-acetate (PMA) in-
duced RANKL expression in memory B cells and pro-
moted osteoclast differentiation in vitro [36]. These
impressive findings emphasize a potential role of effector
B cells in osteoclastogenesis involved in RA. Here, instead
of fixed cells frequently used in the co-culture system
[36, 37], we applied the novel system using macrophage
RAW264 Venus reporter cells to monitor osteoclasto-
genesis co-cultured with live B cells, and showed that
switched-memory B cells did facilitate osteoclastogene-
sis (Fig. 4). These findings suggest that RANKL and
TNF-α, two positive regulators produced by effector
memory B cells, would override the inhibitory effects of
OPG, thereby favoring towards osteoclastogenesis in
particular under inflammatory conditions such as RA.
Based on the findings herein, our current model is
depicted in Fig. 5. The most puzzling issue is the rela-
tionship between RANKL+ effector B cells shown in our
study and FcRL4+ RANKL+ effector B cells [14]. We
found that FcRL4 expression was detectable in SF B cells
of patients with RA; however, it was not appreciably ob-
served in PB B cells of both HC and patients with RA,
even upon any stimulation including IFN-γ (data not
shown). Notably, although FcRL4+ B cells have lower ex-
pression of CD21 than FcRL4– B cells [14], RANKL+ B
cells in our study had higher expression of CD21 than
RANKL– B cells (Additional file 3: Figure S2). Whether
FcRL4+RANKL+ B cells originate from CXCR3+RANKL+
B cells in the PB upon a yet-to-be-identified stimulation,
or are novel subsets immigrated from other lymphoid
tissues, requires further investigation. Another intriguing
issue is whether RANKL+ effector B cells have the po-
tential to differentiate into ACPA-producing cells. Given
that IL-21, a critical cytokine triggering plasma cell dif-
ferentiation, inhibited RANKL expression in B cells
(Fig. 2), a distinct program might operate in the gener-
ation of RANKL+ effector B cells. Ongoing experiments
are underway to address these outstanding issues.
Conclusions
This study has uncovered the mechanism by which
RANKL+ effector B cells are generated in humans.
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Combined stimulation of BCR and CD40 led to high
levels of RANKL expression particularly in switched-
memory B cells, which was further augmented by IFN-
γ. In addition, IFN-γ facilitated the generation of
CXCR3+RANKL+ memory B cells, reminiscent of syn-
ovial B cell phenotype in RA, and these cells in concert
with TNF-α induced osteoclast differentiation in vitro.
Our current findings would provide a novel clue for the
therapeutic strategy to selectively target pathogenic ef-
fector B cells in RA, compared with current anti-CD20
therapy in which all B cells are non-selectively
depleted.
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